Kite Pharma (a subsidiary of Gilead Sciences, Inc.) and Novartis AG are Dominating in the Global CAR-T Cell Therapy Treatment Market in 2020

Global CAR-T Cell Therapy Treatment Market is expected to grow with the CAGR of 30.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-treatment-market

Global CAR-T cell therapy treatment market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global CAR-T cell therapy treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in July 2020, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had received the U.S.FDA approval for Tecartus the only approved CAR-T cell therapy for the treatment of refractory mantle cell lymphoma (MCL). The product has been also granted with Breakthrough Therapy Designation (BTD) from the U.S. FDA. This approval paved the way for the product approval and allowed it to expand its root in the CAR-T cell therapy treatment market.

Kite Pharma (a subsidiary of Gilead Sciences, Inc.) is the dominating player in global CAR-T cell therapy treatment market. The other key players existing in the CAR-T cell therapy treatment market are Autolus, Atara Biotherapeutics, Inc., Amgen Inc., Bellicum Phamaceuticals, Inc., bluebird bio, inc., Adaptimmune Therapeutics plc, Bristol-Myers Squibb Company, Xyphos (a subsidiary of Astellas Pharma Inc.), Johnson & Johnson Services, Inc., BioAtla Inc., AbbVie Inc., Novartis AG, Aurora Biopharma, Tmunity Therapeutics, Cartherics Pty ltd, CARINA BIOTECH, Ziopharm Oncology, Inc., Cellectis SA, Mustang Bio, Sorrento Therapeutics, Inc., Cartesian Therapeutics, Inc., TC BioPharm Limited, Celyad Oncology SA, Tessa Therapeutics Ltd. among others.

CAR-T Cell Therapy Treatment Market

Kite Pharma (a subsidiary of Gilead Sciences, Inc.):

Kite Pharma (a subsidiary of Gilead Sciences, Inc.) is headquartered in California, U.S. and was founded in 2009. The company is focused on the cell therapy by using genetically modified immune cells to target the tumors and the company wants to change the methods for treating the cancer. The company deals in multiple business segments such as HIV products, HCV products, veklury, cell therapy products, trodelvy and other products among which cell therapy products is the market focused segment. The company provides products under categories such as technology and our therapies in which our technology is the market focused category.

For instance,

  • In December 2017, Kite Pharma (a subsidiary of Gilead Sciences, Inc.) had acquired the Cell Design Labs with an aim to enhance the company’s footprint in CAR-T cell therapy treatment and other different cell therapies market. Cell Design Labs is focused on accelerating the research activities related to immunotherapies that are the company’s proprietary molecular modules indicated for cancer treatment. The company is involved in the production of two different technologies of CAR-T cell therapies that is synNotch and throttle. This acquisition has also helped the company to enhance their R&D platform with innovative technologies.

The company has wide presence across North America and Europe. The company also has various subsidiary companies including Cell Design Labs, Inc. (U.S.), Fosun Kite Biotechnology Co., Ltd (China) and others.

Novartis AG:

Novartis AG is headquartered in Basel, Switzerland and was founded in 1996. The company focuses on innovating new solutions for various health care challenges. The company operates its business via two business segments including innovative medicines and Sandoz in which innovative medicines is the market focused segment. The company has wide range of products under categories which are cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience and respiratory in which cancer is the market focused category.

For instance,

  • In October 2020, Novartis AG had received the receipt of marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for the manufacturing and distribution of the Kymriah (tisagenlecleucel) mainly for the patients in Japan. The FBRI manufacturing site will be considered as one of the first commercial production site in Asia for the CAR-T cell therapy. As the company has the largest global availability of CAR-T cell therapy which helped the company to boost up their market position in terms of innovative technology in the field of oncology and also allowed the company to attain a lucrative growth in the market.

The company has presence across Americas, Asia-Pacific, Europe and Middle East and Africa. The company also has various subsidiaries including Novartis Argentina S.A. (Argentina), Novartis Australia Pty Ltd (Australia), Novartis Austria GmbH (Austria), Novartis Pharma NV (Belgium), Sandoz (China) Pharmaceutical (China) among others.